Activity of the novel immunomodulatory compound tucaresol against experimental visceral Leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1494-1498

  Smith, Aden C ^a   Yardley, Vanessa ^a   Rhodes, John ^b   Croft, Simon L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STIBOGLUCONATE SODIUM; TUCARESOL;

AMASTIGOTE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; LEISHMANIA DONOVANI; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BENZALDEHYDES; BENZOATES; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C;

EID: 0034076993     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1494-1498.2000     Document Type: Article

References (39)

1. Adinolfi, L. E., and P. F. Bonventre. 1985. Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,665-1). Am. J. Trop. Med. Hyg. 34:270-277.
2. Adinolfi, L. E., P. F. Bonventre, M. Vander Pas, and D. A. Eppstein. 1985. Synergistic effect of Glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. Infect. Immun. 48:409-416.
3. Alvar, J., C. Cañavate, B. Gutiérrez-Solar, M. Jiménez, F. Laguna, R. López-Vélez, R. Molina, and J. Moreno. 1997. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10:298-319.
4. Arya, R., P. E. Rolan, R. Wootton, J. Posner, and A. J. Bellingham. 1996. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br. J. Haematol. 93:817-821.
5. Ashford, R. W., P. Desjeux, and P. DeRaadt. 1992. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol. Today 8:104-105.
6. Avila, J. L., F. Biondo, H. Monzon, and J. Convit. 1982. Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy. Am. J. Trop. Med. Hyg. 31:53-59.
7. Badaro, R., C. Nascimento, J. S. Carvalho, F. Badaro, D. Russo, J. L. Ho, S. G. Reed, W. D. Johnson, Jr., and T. C. Jones. 1994. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170: 413-418.
8. Barrett, M. P., G. H. Coombs, and J. C. Mottram. 1999. Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends Microbiol. 7:82-88.
9. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
10. Berman, J. D., R. Badaro, C. P. Thakur, K. M. Wasunna, K. Behbehani, R. Davidson, F. Kuzoe, L. Pang, K. Weerasuriya, and A. D. M. Bryceson. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. W. H. O. 76:25-32.
11. Bhakuni, V., U. K. Sigha, G. P. Dutta, H. B. Levy, and R. K. Maheshwari. 1996. Killing of Leishmania donovani amastigotes by poly ICLC in hamsters. J. Interferon Cytokine Res. 16:321-325.
12. Bogdan, C., and M. Rollinghoff. 1998. The immune response to Leishmania: mechanisms of parasite control and evasion. Int. J. Parasitol. 28:121-134.
13. Bosma, G. C., R. P. Custer, and M. J. Bosma. 1983. A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530.
14. Buates, S., and G. Matlashewski. 1999. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. 179:1485-1494.
15. Cenini, P., N. Berhe, A. Hailu, K. McGinnes, and D. Frommel. 1993. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168:986-994.
16. Chen, H., S. Hall, B. Heffernan, N. T. Thompson, M. V. Rogers, and J. Rhodes. 1997. Convergence of Schiff base costimulatory signaling and TCR signaling at the level of mitogen-activated protein kinase ERK2. J. Immunol. 159:2274-2281.
17. Chen, H., S. Hall, B. Zheng, and J. Rhodes. 1997. Potentiation of the immune system by Schiff base-forming drugs. Biodrugs 7:217-231.
18. Cillari, E., F. Arcoleo, M. Dieli, R. D'Agostino, G. Gromo, F. Leoni, and S. Milano. 1994. The macrophage-activating tetrapeptide tuftsin induces nitric oxide synthesis and stimulates murine macrophages to kill Leishmania parasites in vitro. Infect. Immun. 62:2649-2652.
19. Cohen, H. 1979. Induction of delayed-type sensitivity to Leishmania parasite in a case of leishmaniasis cutanea diffusa with BCG and cord-factor (trehalose-6-6′ dimycolate). Acta Dermatovener. 59:547-549.
20. Coleman, R. E., J. D. Edman, and L. H. Semprevivo. 1988. Effect of cimetidine and 2′-deoxyguanosine on the development of Leishmania mexicana in BALB/c mice. Trans. R. Soc. Trop. Med. Hyg. 82:232-233.
21. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28:669-680.
22. Gradoni, L., A. Bryceson, and P. Desjeux. 1995. Treatment of Mediterranean visceral leishmaniasis. Bull. W. H. O. 73:191-197.
23. Grimaldi, G. F., P. L. Moriearty, and R. Hoff. 1980. Leishmania mexicana in C3H mice: BCG and levamisole treatment of established infections. Clin. Exp. Immunol. 41:237-242.
24. Guru, P. Y., A. K. Agrawal, U. K. Singha, A. Singhal, and C. M. Gupta. 1989. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett. 245:204-208.
25. Honore, S., Y. J.-F. Garin, A. Sulahian, J.-P. Gangneux, and F. Derouin. 1998. Influence of the host and parasite strain in a mouse model of visceral Leishmania infantum infection. FEMS Immunol. Med. Microbiol. 21:231-239.
26. Kaye, P. M. 1995. Costimulation and the regulation of antimicrobial immunity. Immunol. Today 16:423-427.
27. Kaye, P. M., M. Gorak, M. Murphy, and S. Ross. 1995. Strategies for immune intervention in visceral leishmaniasis. Ann. Trop. Med. Parasitol. 89:75-81.
28. Kiderlen, A. F., and P. M. Kaye. 1990. A modified colorimetric assay of macrophage activation for intracellular cytotoxicity against Leishmania parasites. J. Immunol. Methods 127:11-18.
29. Kirkwood, J. M., S. Schuchter, S. Donnelly, L. Stover, P. Drobins, T. L. Whiteside, J. P. Burnhant, C. K. Heitman, and J. M. Johnston. 1997. A novel immunopotentiating agent, tucaresol: results from a multicenter, pilot study in patients with metastatic melanoma. Proc. Am. Assoc. Cancer Res. 38:402.
30. Murray, H. W. 1997. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J. Infect. Dis. 175:1477-1479.
31. Murray, H. W., J. D. Berman, and D. Wright. 1988. Immunochemotherapy for Leishmania donovani infection: γ Interferon plus pentavalent antimony. J. Infect. Dis. 157:973-978.
32. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behaviour of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J. Exp. Med. 185:867-874.
33. Murray, H. W., M. J. Oca, A. M. Granger, and R. D. Schreiber. 1989. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Investig. 83:1253-1257.
34. Nabors, G. S., L. C. Afonso, J. P. Farrell, and P. Scott. 1995. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl. Acad. Sci. USA 92:3142-3146.
35. Neal, R. A., and S. L. Croft. 1984. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14:463-475.
36. Rhodes, J., H. Chen, S. R. Hall, J. E. Beesley, D. C. Jenkins, P. Collins, and B. Zheng. 1995. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature 377:71-75.
37. Sundar, S., S. G. Reed, S. Sharma, A. Mehrotra, and H. W. Murray. 1997. Circulating T helper 1 (TH1) cell and TH2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56:522-525.
38. Sundar, S., F. Rosenkaimer, and H. W. Murray. 1994 Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon. J. Infect. Dis. 170:659-662.
39. Wang, C. C. 1997. Validating targets for antiparasite chemotherapy. Parasitology 114:S31-S44.